Affiliation:
1. University Of Cambridge
2. Experimental Medicine and Immunotherapeutics, University of Cambridge
3. jjm1003@medschl.cam.ac.uk
4. Sosei Heptares
5. SoseiHeptares
Abstract
Abstract
We describe a structural and functional study of the apelin receptor, a G protein-coupled receptor (GPCR) that binds two endogenous peptide ligands, apelin and Elabela/Toddler (ELA), to regulate cardiovascular development and function. Characterisation of novel, naturally occurring apelin receptor variants from the UK Genomics England 100,000 Genomes Project, in combination with AlphaFold2 modelling, identified T892.64 as an important residue in the ELA binding site, and R1684.64 as forming extensive interactions with the C-termini of both peptides. Base editing to introduce an R/H1684.64 variant into stem cell-derived cardiomyocytes demonstrated that this residue is critical for receptor binding and function in a clinically relevant setting. Additionally, we present a novel apelin receptor crystal structure bound to the G protein-biased, small molecule agonist, CMF-019, which revealed a deeper binding mode versus peptides at lipophilic pockets between transmembrane helices associated with GPCR activation. Overall, the data provide proof-of-principle for using genetic variation to fast-track the identification and characterisation of key sites that regulate receptor-ligand engagement, potentially informing future drug design.
Publisher
Research Square Platform LLC
Reference70 articles.
1. O’Dowd BF et al (1993) A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 136, 355–360
2. A comprehensive map of molecular drug targets;Santos R;Nat Rev Drug Discovery,2017
3. Trends in GPCR drug discovery: new agents, targets and indications;Hauser AS;Nat Rev Drug Discovery,2017
4. G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Man Drugs?;Sriram K;Mol Pharmacol,2018
5. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor;Tatemoto K;Biochem Biophys Res Commun,1998